Peptonic closes a private placement transaction with Vidarstiftelsen

Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has closed a private placement transaction with Vidarstiftelsen. The transaction comprised 11 million shares at a subscription price of SEK 2.00 per share. The subscription price was SEK 0.01 above the volume weighted average trading price of the Peptonic share for the period 13th thru 19th of November, 2019. Net proceeds of this placement are SEK 22 million.

– We are honoured and proud that Vidarstiftelsen has decided to invest in Peptonic, says Hans von Celsing, Chairman of the Board of Peptonic Medical. This capital injection allows the Company to accelerate its VagiVital marketing and launch activities, and to speed up new product development and evaluation.

Statement by Vidarstiftelsen;

– We think the mission of Peptonic is important as it serves the purpose of improving the health of women. It’s gratifying for us to be able to contribute to the continued development of Peptonic and to support the activities of making Peptonic’s products widely available. We strongly believe in a continued positive development of the Company and its product portfolio.

For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893

Juhani Selvani
Mobil: +46 733 58 78 80

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 21st November 2019. 

About Vidarstiftelsen

Vidarstiftelsen is foundation with a mission to support the general public. The mission is to be fulfilled through grants given for e.g. scientific research, preparation of teaching and education, health care and hospital care, culture and environmental conservation. The income of the capital is to be used for the above mission.

About VagiVital®

VagiVital®is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects. 

VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 and has since then also been launched in Finland, Denmark, Norway and the United Kingdom (see 

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital®is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also holds Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (, ticker: PMED) in Stockholm, Sweden. 

For more